Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shengqian Xu

Showing results (1-10 of 128) with videos related to

Pageof 13
Sort By:
Zhonghua Nei Ke Za Zhi|January 15, 2015
[Treat to target in ankylosing spondylitis]Shengqian Xu, Feng Huang
Clinical Rheumatology|May 5, 2022
Rebuttal letter referring to the article "Synergy of sarcopaenia and vitamin D deficiency in vertebral osteoporotic fractures in rheumatoid arthritis"Yiran Chu, Shengqian Xu
Biomedical Reports|March 21, 2014
TNF inhibitor therapy for rheumatoid arthritisXixi Ma, Shengqian Xu
Heliyon|September 10, 2024
Tumor-derived exosome PPP3CB induce gemcitabine resistance by regulating miR-298/STAT3 in pancreatic cancerChaojun Wang, Shengqian Xu, Yong Qin
Immunity, Inflammation and Disease|January 27, 2023
Systemic lupus erythematosus associated with multiple myeloma: Two case reports and a literature reviewLi Lian, Kang Wang, Shengqian Xu
Immunologic Research|January 10, 2026
Current and projected trends in rheumatoid arthritis among postmenopausal women in the U.S.: a population-based analysis of the Global Burden of Disease Study 2021, with projections to 2035Wen Liu, Xiaoling Mo, Shengqian Xu
Rheumatology International|July 21, 2012
Is RUNX3 a new player in the pathogenesis of ankylosing spondylitis?Zhen Zeng, Zhenhua Duan, Shengqian Xu, et al.
Rheumatology International|November 8, 2011
Osteoprotegerin and RANKL in the pathogenesis of rheumatoid arthritis-induced osteoporosisShengqian Xu, Yu Wang, Jingqiu Lu, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|December 5, 2017
Interleukin-23 receptor polymorphism (rs10889677 A/C) in ankylosing spondylitis: Meta-analysis in Caucasian and Asian populationsRenfang Han, Qing Xia, Shengqian Xu, et al.
Medicine|June 17, 2022
Combination therapy of tacrolimus, high doses of glucocorticosteroids, and cyclophosphamide against existing historical treatment for patients in severe conditions of interstitial lung diseases complicated with dermatomyositis: A retrospective analysisLi Lian, Mu Li, Yingchun Li, et al.
Pageof 13

Showing results (1-10 of 128) with videos related to

Sort By:
Pageof 13
Zhonghua Nei Ke Za Zhi|January 15, 2015
[Treat to target in ankylosing spondylitis]Shengqian Xu, Feng Huang
Clinical Rheumatology|May 5, 2022
Rebuttal letter referring to the article "Synergy of sarcopaenia and vitamin D deficiency in vertebral osteoporotic fractures in rheumatoid arthritis"Yiran Chu, Shengqian Xu
Biomedical Reports|March 21, 2014
TNF inhibitor therapy for rheumatoid arthritisXixi Ma, Shengqian Xu
Heliyon|September 10, 2024
Tumor-derived exosome PPP3CB induce gemcitabine resistance by regulating miR-298/STAT3 in pancreatic cancerChaojun Wang, Shengqian Xu, Yong Qin
Immunity, Inflammation and Disease|January 27, 2023
Systemic lupus erythematosus associated with multiple myeloma: Two case reports and a literature reviewLi Lian, Kang Wang, Shengqian Xu
Immunologic Research|January 10, 2026
Current and projected trends in rheumatoid arthritis among postmenopausal women in the U.S.: a population-based analysis of the Global Burden of Disease Study 2021, with projections to 2035Wen Liu, Xiaoling Mo, Shengqian Xu
Rheumatology International|July 21, 2012
Is RUNX3 a new player in the pathogenesis of ankylosing spondylitis?Zhen Zeng, Zhenhua Duan, Shengqian Xu, et al.
Rheumatology International|November 8, 2011
Osteoprotegerin and RANKL in the pathogenesis of rheumatoid arthritis-induced osteoporosisShengqian Xu, Yu Wang, Jingqiu Lu, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|December 5, 2017
Interleukin-23 receptor polymorphism (rs10889677 A/C) in ankylosing spondylitis: Meta-analysis in Caucasian and Asian populationsRenfang Han, Qing Xia, Shengqian Xu, et al.
Medicine|June 17, 2022
Combination therapy of tacrolimus, high doses of glucocorticosteroids, and cyclophosphamide against existing historical treatment for patients in severe conditions of interstitial lung diseases complicated with dermatomyositis: A retrospective analysisLi Lian, Mu Li, Yingchun Li, et al.
Pageof 13